{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:08:25Z","timestamp":1773421705094,"version":"3.50.1"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2012]]},"DOI":"10.2169\/internalmedicine.51.7472","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T22:52:32Z","timestamp":1346799152000},"page":"2337-2340","source":"Crossref","is-referenced-by-count":32,"title":["Pulmonary Arterial Hypertension Caused by Treatment with Dasatinib for Chronic Myeloid Leukemia -Critical Alert-"],"prefix":"10.2169","volume":"51","author":[{"given":"Makoto","family":"Sano","sequence":"first","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Saotome","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Urushida","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Katoh","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Satoh","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Internal Medicine III, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideharu","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25: 3908-3914, 2007.","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"2","unstructured":"2. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (esc) and the european respiratory society (ers), endorsed by the international society of heart and lung transplantation (ishlt). Eur Heart J 30: 2493-2537, 2009."},{"key":"3","unstructured":"3. Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data. Cancer 98: 2636-2642, 2003."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541, 2006.","DOI":"10.1056\/NEJMoa055229"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted cml patient. Bone Marrow Transplant 43: 967-968, 2009.","DOI":"10.1038\/bmt.2008.415"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 36: e4-e6, 2012.","DOI":"10.1016\/j.leukres.2011.08.007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 11: 30, 2011.","DOI":"10.1186\/1471-2466-11-30"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 38: 218-220, 2011.","DOI":"10.1183\/09031936.00154210"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33: 861-864, 2009.","DOI":"10.1016\/j.leukres.2008.09.026"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125: 2128-2137, 2012.","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc051946"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61: 736, 2006.","DOI":"10.1136\/thx.2006.064097"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24838"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16. Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 81-88, 2008.","DOI":"10.1164\/rccm.200707-1037OC"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182: 1171-1177, 2010.","DOI":"10.1164\/rccm.201001-0123OC"},{"key":"17","unstructured":"18. Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F. Nilotinib: Optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 3: 89-101, 2009."},{"key":"18","doi-asserted-by":"crossref","unstructured":"19. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the bcr-abl inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063, 2007.","DOI":"10.1182\/blood-2007-07-102061"},{"key":"19","doi-asserted-by":"crossref","unstructured":"21. Pullamsetti SS, Berghausen EM, Dabral S, et al. Role of src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 32: 1354-1365, 2012.","DOI":"10.1161\/ATVBAHA.112.248500"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/17\/51_51.7472\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:44:14Z","timestamp":1621446254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/17\/51_51.7472\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":19,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.51.7472","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}